Medi-Caps swings to ₹303.75 lacs loss as revenue halves
Consolidated revenue fell 51% to ₹1,244.85 lacs; standalone swung from profit to loss. Pharma division blames US political instability.
What's new with Medi-Caps Ltd.
- Revenue from operations halved to ₹1,244.85 lacs from ₹2,547.71 lacs.
- Consolidated net loss widened to ₹303.75 lacs from ₹57.10 lacs.
- Standalone swung from ₹55.51 lacs profit to ₹13.87 lacs loss.
Why this matters for Medi-Caps Ltd.
The scale of the revenue collapse — halved in a single year — points to deep structural issues in the pharma export business, especially the US market. At a ₹35 crore market cap, the company is now loss-making on both standalone and consolidated bases, leaving little margin for error.
What we're watching
- Whether US political conditions stabilise for the pharma division.
- Any restructuring or cost-cutting measures announced.
- Whether the standalone business can return to profitability.
The full read
Medi-Caps reported a sharp deterioration in FY26. Consolidated revenue halved to ₹1,244.85 lacs, and net loss ballooned to ₹303.75 lacs. The standalone entity, which had been profitable, also slipped into a loss of ₹13.87 lacs. The primary culprit: the pharma division, which generates the bulk of revenue, was hit by political instability in the US, its main export market. Meanwhile, the real estate segment, already weak, did not compensate. At a mere ₹35 crore market cap, the company is now loss-making on both bases. The next test is whether the US market recovers — and whether management can stem the bleeding in the pharma arm.